Compare Amgen, Inc. (AMGN) vs Comcast Corporation (CMCSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Comcast Corporation — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Comcast Corporation trades at $23.71 (market cap $84.20B). The key difference: Amgen, Inc. is far larger — about 2.3× Comcast Corporation's market cap, and Comcast Corporation pays the higher dividend (5.6%). Which is the better fit depends on your goals.
| AMGN | CMCSA | |
|---|---|---|
Market Cap | $196.12B | $84.20B |
Sector | Health | Media |
52-Week High | $388.16 | $33.81 |
52-Week Low | $271.18 | $22.32 |
Enterprise Value | $241.41B | $169.34B |
Dividend Yield | 2.77% | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
CMCSA trades at $23.57, up 0.96% with strong fundamentals including a low P/E of 4.62 and net income margin of 15%. Recent earnings beats and a $2.14B acquisition of ITV's media unit signal strategic growth. Technicals are bearish with support at $23, while analyst consensus remains bullish with a $30.94 price target.
Outlook: Undervalued with robust cash flow and dividend yield, but weighed by bearish technicals and spin-off uncertainty. Key risks include integration challenges from acquisitions and competitive pressures in media and broadband sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →
